Peptide Therapeutics Market is expected to reach US$ 50,003.15 million by 2027

PRESS RELEASE BY The Insight Partners 22 Feb 2021

Share this press on

Cancer is the Largest Segment by Application in the Peptide Therapeutics Market From 2020–2027

According to our new research study on " Peptide Therapeutics Market Forecast to 2027 – COVID-19 Impact and Global Analysis – by Type, Route of Administration, Synthesis Technology, Application, and Geography," the market size was valued at US$ 50,003.15 million by 2027 from US$ 26,998.21 million in 2020; it is estimated to grow with a CAGR of 9.2% from 2020-2027. The report highlights the trends and drivers prevailing in the peptide therapeutics market.

Based on the application, the global peptide therapeutics market is segmented into cancer, cardiovascular disorder, metabolic disorder, respiratory disorder, pain, and dermatology. The cancer segment held the largest market share of the market in 2020. Cancer is a major health problem around the world, with increasing incidence of the disease extensively. For instance, according to a study published by World Health Organization (WHO), data published in 2020, there were 19 292 789 cancer cases across the world, and it is estimated to reach 28 887 940 by 2040. 

Peptide Therapeutics Market

Peptide Therapeutics Market Report - Size & Share 2027

Download Free Sample

Peptide Therapeutics Market Forecast to 2027 - Global Analysis By Type (Generic and Innovative); Route of Administration (Parenteral, Oral, Mucosal, Pulmonary, and Others); Synthesis Technology (Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), and Hybrid Technology); Application (Cancer, Cardiovascular Disorder, Metabolic Disorder, Respiratory Disorder, and Pain, Dermatology), and Geography

Several new therapies are being studied to treat cancer, of which peptide therapy has gained high importance owing to the advantages offered by peptides. Chemotherapy based on peptides offer advantages such as low molecular weight, the ability to target tumor cells, and low toxicity in normal cells. 

Also, growing research on peptides to treat cancer is likely to drive market growth during the forecast period. For instance, in 2018, biologists at the Massachusetts Institute of Technology, US, developed a new peptide that disrupts a protein called Mcl-1, which helps cancer cells avoid cellular suicide. The peptide blocks the protein Mcl-1 which forces the cancer cell to undergo programmed cell death. Such developments have encouraged more research and developments on peptide therapeutics that can evolve cancer treatments. Thus, these factors have favored the market growth during 2020–2027.

However, the metabolic disorder segment is estimated to register the highest CAGR in the market during the forecast period. Certain chemical reactions in the human body disrupt the metabolic processes in the body, which is termed a metabolic disorder. Lethargy, jaundice, weight loss, and seizures are some of the symptoms of metabolic disorder. Metabolic disorders are developed when some organs of the body do not function properly. For instance, in diabetes, the pancreas produces little or no insulin. Thus, the growing demand for therapies for metabolic disorders and the rising prevalence of lifestyle disease thus is likely to boost the growth of the segment. Many companies operating in this segment are conducting robust research activities to develop peptides for metabolic disorders. For instance, Creative Peptides, a company specializing in producing bioactive peptides, is carrying out extensive research on peptides for diabetes.

Eli Lilly and Company, Amgen Inc., TEVA PHARMACEUTICAL INDUSTRIES LTD, Polypeptide Group, EVER Pharma GmbH, Bristol-Myers Squibb Company, Novo Nordisk A/S, Sanofi, AstraZeneca PLC, and Glaxosmithkline PLC are among the several players engaged in addressing the demands for peptide therapeutics market growth. 

The report segments the peptide therapeutics market as follows:

Based on the type, the market is segmented into imm generic and innovative. Based on the route of administration, the market is segmented into parenteral, oral, mucosal, pulmonary, and others On the basis of synthesis technology, the market is segmented into solid phase peptide synthesis (SPPS), liquid phase peptide synthesis (LPPS), and hybrid technology. Based on application, the market is classified into cancer, cardiovascular disorder, metabolic disorder, respiratory disorder, pain, and dermatology. Based on geography, the hospital supplies market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France), Asia Pacific (China, Japan, India), the Middle East & Africa (the UAE, Saudi Arabia, and South), and South & Central America (Brazil).

Contact Us
Phone: +1-646-491-9876
Email Id:

Download Free PDF Brochure